IMMUNOCORE hires ASTRAZENECA veteran, Bahija Jallal, as Chief Executive Officer to take over from interim CEO, Andrew Hotchkiss. 11 months ago, Mr. Hotchkiss stepped up from the Chief Commercial Officer role following the departure of then-CEO, Dr Eliot Forster.
Extract: “Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that Bahija Jallal has been appointed as Chief Executive Officer and Director of the Board.
With more than 25 years of international leadership experience within the pharmaceutical industry, Bahija joins Immunocore from AstraZeneca, where she is President of MedImmune, its global biologics research and development arm, and a member of the senior executive team reporting to the CEO.
Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She serves on the Board of ANTHEM, INC. in Indianapolis, Indiana and on the Board of Trustees of the Johns Hopkins University in Baltimore, Maryland. She is a member of the Government-University-Industry Research Roundtable (GUIRR) of the National Science Foundation and is the immediate past President of the board of the Association of Women in Science. In 2017, Bahija was named Woman of the Year by the Healthcare Businesswomen’s Association.”